JP2932684B2 - Nutritional composition for patients with thrombotic diseases - Google Patents

Description

Description: FIELD OF THE INVENTION The present invention relates to nutrition for patients with thrombotic diseases in which potato protein and / or an enzymatic hydrolyzate thereof is mixed with an oil or fat containing α-linolenic acid and linoleic acid at a high level. Composition.

2. Description of the Related Art In addition to crystalline amino acids, animal proteins such as casein or their enzymatic hydrolysis are used as nitrogen sources in nutritional compositions conventionally used for enteral and oral nutrition. Things are used. However, animal proteins and their enzymatic hydrolysates
Despite excellent nutritional value, the effect of increasing plasma lipids is generally observed (Caroll, KK Dietary pro
tein in relation to plasma cholesterol levels and
Atherosclerosis. Nutr. Rev. 36 : 1-5; 1978), as a nitrogen source of a nutritional composition intended to have a medicinal effect of improving lipid metabolism, a soy protein having a relatively high nutritional value among vegetable proteins. Alternatively, an enzymatic hydrolyzate thereof is used. Pharmaceutical disadvantages such as stability and solubility, which are problematic when using crystalline amino acids as a nitrogen source in the nutritional composition, are solved by using enzymatic hydrolysates of proteins and are nutritionally equivalent. The above effectiveness has already been proposed in JP-A-64-20060. In clinical practice, plasma lipid levels are regarded as a risk factor in terms of primary prevention of atherosclerosis (The Lipid Research
Clinics Coronary Primary Prevention Trial Result
s: I, II. JAMA 251 : 351-374; 1984). On the other hand, an increase in platelet function has been reported in thrombotic diseases such as cerebral infarction and myocardial infarction (Masahiro Maruyama: Cerebral infarction and blood coagulation, Japan Medical Association, 88, 35).
2-360; 1982), and antiplatelet drugs such as aspirin and ticlopidine are generally used as pharmacotherapy to prevent recurrence of these diseases (Eio Shio: Prevention of recurrence, Pr
o. Med. 8 , 1109-1112; 1988).

We focused on a vegetable protein that has an inhibitory effect on plasma lipid elevation among nutritional materials, and examined its effect on platelet function by feeding rats with a cholesterol diet. However, collagen aggregation was clearly enhanced for platelets. Therefore, soybean tampan may promote the formation of thrombus, and the nutritional composition containing soybean protein or its enzymatic hydrolyzate cannot be expected to have the medicinal effect of preventing thrombotic diseases.

An object of the present invention is to provide a nutritional composition having an excellent antiplatelet action and lipid lowering action and effective for prevention and treatment of thrombotic diseases.

Means for Solving the Problems In order to solve the problems, the present inventors have conducted various studies and found that potato protein and / or its enzymatic hydrolyzate and α-linolenic acid and linoleic acid as fatty acid components were increased. The composition containing fats and oils containing is found to have excellent antiplatelet action and plasma lipid lowering action,
The present invention has been completed.

That is, the present invention provides a nutritional composition for a thrombotic disease patient, which comprises a potato protein and / or an enzymatic hydrolyzate thereof, and an oil containing a high content of α-linolenic acid and linoleic acid as a fatty acid component. It is.

Potato tank material and its enzymatic hydrolyzate, like other plant proteins, are useful protein materials that have a plasma lipid elevation inhibitory effect and also have an inhibitory effect on platelet aggregation enhancement . By combining this with an oil or fat containing a high amount of α-linolenic acid and linoleic acid as fatty acid components, it is possible to remarkably suppress plasma lipid elevation and platelet aggregation.

Potato protein used in the present invention is separated after removing starch from potatoes in a starch purification step, concentrated,
It is manufactured by drying and is mainly used as a raw material for protein for feed. Potato protein can enhance digestibility and nutritional value by enzymatic hydrolysis, and at the same time improve solubility, color and texture (Japanese Patent Application Laid-Open No. 64-20060). Can be easily used. In the nutritional composition of the present invention, potato protein or its enzymatic hydrolyzate can be used alone or in combination. Potato protein and its enzymatic hydrolyzate
From the viewpoint of satisfying the required amount of protein for adults, it is desirable to contain 10 to 30% by weight.

It is also desirable that the nutritional composition contains 5 to 20% by weight of fats and oils containing α-linolenic acid and linoleic acid as fatty acid components in view of satisfying the nutritional requirements of adults. Examples of the fats and oils containing high amounts of α-linolenic acid and linoleic acid used in the present invention include soybean oil, safflower oil, radish oil, corn oil, wheat germ oil, rapeseed oil, evening primrose oil and the like. These fats and oils can be used alone or in combination.

The nutritional composition of the present invention has a composition as shown in Table 1, for example.

The nutritional composition of the present invention is ingested orally or enterally as a nutrient once or several times a day in accordance with "Japanese Nutrition Requirements" (1984).

The nutritional composition of the present invention has excellent antiplatelet action and lipid-lowering action, so it is useful for prevention and treatment of arteriosclerosis and thrombotic diseases, and is suitable for nutritional supplementation of myocardial infarction and stroke, among which It is useful for preventing recurrence of cerebral infarction.

Examples Hereinafter, the present invention will be described more specifically with reference to examples.

Example 1 A 0.5% cholesterol diet was given to 5-week-old male SD rats, blood was collected from the subclavian vein on the 8th week, the plasma cholesterol concentration was measured by the enzyme method, and the 9-week fasted for 24 hours. Then, using a platelet-rich plasma (PRP) prepared from arterial blood, platelet aggregation was measured using an aggregometer (NBS hematotracer 8).
01). The composition (%) of the experimental diet is protein 2
0, mineral mixture 4, vitamin mixture 1, choline chloride 0.1
5, cellulose 2, corn oil 5, cholesterol 0.5, sodium cholate 0.125, sucrose adjusted to 100. As proteins, casein, soy protein,
Potato proteins were used respectively. A casein group containing no cholesterol was used as a control.

The plasma cholesterol concentration was significantly increased in the casein group as compared with the control, but the plasma cholesterol increase was suppressed in the soy protein and potato protein groups, which are vegetable proteins (Table 2).

Platelet aggregation, when collagen is used as an aggregation-inducing substance,
At the maximum aggregation rate, the soy protein group was enhanced about twice as much as the control, whereas the potato protein group was clearly inhibited from increasing the aggregation (Table 3).

Example 2 Similar to Example 1, 0.5% SD male rats of 5 weeks of age
A cholesterol diet was provided, blood was collected from the subclavian vein every two weeks, and the plasma cholesterol concentration was measured, and the platelet aggregation ability was measured at the eighth week. The composition (%) of the experimental diet is protein 20,
The mixture was adjusted to 100 with mineral mix 4, vitamin mix 1, choline chloride 0.15, cellulose 2, fats and oils 5, cholesterol 0.5, sodium cholate 0.125, and sucrose. An experimental diet containing casein in protein, safflower oil in fats and oils was a control group, an experimental diet containing potato protein enzyme hydrolyzate in protein and fats and oils was a peptide group, an experimental diet containing safflower oil in fats and oils, and casein and wheat in fats and oils. An experimental diet containing a blended oil of germ oil and soybean oil is the same as the experimental diet of the blended oil group, an experimental diet containing the enzymatically decomposed product of potato protein for the protein, and the oil and fat is the same experimental diet as the peptide + blended oil group and the control group. Aspirin 100mg / kg / day 3 days before autopsy
The aspirin group was obtained by continuously throwing. Plasma cholesterol levels were increased in the peptide group and the blended oil group, but were significantly suppressed compared to the control group. Furthermore, no increase in plasma cholesterol was observed in the peptide + blend oil group, and the additive effect of the peptide and the blend oil was evident (FIG. 1). Platelet aggregation tended to be lower in the peptide group and the blended oil group than the control group at the maximum aggregation rate when collagen was used as the aggregation-inducing substance, but significantly lower in the peptide + blended oil group. Inhibition of platelet aggregation was observed, and the effect was similar to that of the aspirin group. (FIG. 2) Effects of the Invention As is clear from the above, the nutritional composition of the present invention has both excellent plasma lipid elevation inhibitory activity and platelet aggregation enhancement inhibitory effect, and prevents arteriosclerosis and thrombotic diseases. And is effective for treatment.

[Brief description of the drawings]

FIG. 1 shows the cholesterol elevation inhibitory effect in Example 2, and shows the total cholesterol in plasma collected weekly from the subclavian vein of rats (n = 9 to 10) fed a cholesterol-supplemented diet freely for 8 weeks. It is a measurement result. FIG. 2 shows the platelet aggregation inhibitory action in Example 2,
Using platelet-rich plasma from rats (n = 6 to 8) who had been allowed to freely take a diet containing cholesterol for 8 weeks, collagen (20
(g / ml).

Continuation of the front page (51) Int.Cl. ⁶ Identification symbol FI A61K 31/23 602 A61K 31/23 602 38/00 37/02 (72) Inventor Yoshiro Kitahara 1-1 Suzukicho, Kawasaki-ku, Kawasaki-shi, Kawasaki, Kanagawa Prefecture (72) Inventor Eiji Sukekawa 1-5-8 Kyobashi, Chuo-ku, Tokyo Ajinomoto Co., Inc. (56) References JP-A 1-20060 (JP, A) JP-A Sho 63-309162 (JP, A) (58) Fields investigated (Int. Cl. ⁶ , DB name) A23L 1/30 A23J 3/14 A61K 31/23 A61K 38/01 A61K 38/16 A23J 3/34 JICST file (JOIS) JAFIC file (JOIS)

Claims (4)

(57) [Claims] 1. A nutritional composition for a thrombotic disease patient, comprising a potato protein and / or an enzymatic hydrolyzate thereof, and an oil containing a high content of α-linolenic acid and linoleic acid as fatty acid components. . 2. The nutritional composition according to claim 1, comprising 10 to 30% by weight of potato protein and / or enzymatic hydrolyzate thereof. 3. The method according to claim 1, wherein the fat or oil is contained in an amount of 5 to 20% by weight.
A nutritional composition as described. 4. The nutritional composition according to claim 1, which is for oral or enteral use.